Opinion
Video
Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs
Faculty share insights into the treatment strategies using CD38-directed monoclonal antibodies (mAbs) in patients with AL amyloidosis.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
The segment focuses on the safety of daratumumab in light chain (AL) amyloidosis. The phase 2 trial at Boston University showed minimal toxicity with intravenous administration, mainly infusion-related reactions that significantly reduced with subcutaneous use. The primary observed adverse effect is an increased risk of infections, particularly pneumonia. Lymphopenia and immunosuppression are potential but less pronounced adverse effects compared with those in multiple myeloma.
The discussion also highlights the cautious use of dexamethasone in combination therapies, which often necessitates reduction. Daratumumab is deemed safe with negligible neurotoxicity, in contrast to the potential neuropathy risks of other chemotherapeutic agents. The importance of supportive care for patients with multi-organ involvement is emphasized, underlining the need for an engaged medical team, including nephrologists and cardiologists, to address potential complications during therapy.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
